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Sm_uary A detailed casenote review was performed on all 65 patients registered with testicular non-
seminomatous germ cell tumours (NSGCT) dunrng 1989 under the Scottish Cancer Registration Scheme.
Details of management at presentation and 2 years following diagnosis were recorded and analysed. In a small
number of patients an unacceptable delay in diagnosis was noted. Variation was found in the frequency and
type of investigations performed on patients placed on surveillance, types of chemotherapy regimens used and
numbers of patients entered into trials. Three per cent of patients had a biopsy of the contralateral testis and
27% of patients defaulted from clinic attendance. Considerable variation in the management of testicular
NSGCT in Scotland has been identified. The introduction of management guidelines should result in a more
consistent approach to the care of these patients. Support, both financial and psychological, may reduce the
unacceptable rate of default.
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Testicular germ cell tumours are now the commonest cancer
in men aged under 40 in Scotland (Sharp et al., 1993a). The
age-standardised incidence rate of testicular NSGCT in Scot-
land for 1988-90 was 2.3:100000, and has risen from
1.8:100000 for 1975-77 (Sharp et al., 1993b). Effective
chemotherapy has transformed what was invariably a fatal
disease, once it had metastasised, to one which is usually
curable (Ellis and Sikora, 1987). Cure rates may be related to
the ability to give effective treatment and it has been sug-
gested that results are better when there is a particular exper-
tise in the treatment of the disease (Harding et al., 1993).
Orchidectomy followed by intensive surveillance, which is
expensive in clinic and medical time, is now considered the
accepted management for most patients with stage I teratoma
(Peckham et al., 1982; Horwich, 1993). Patients with poor
prognostic histological features, and where the disease has
spread beyond the testis, require cytotoxic chemotherapy.
Cure rates as high as 90% can now be expected for good
prognosis metastatic disease (Horwich, 1989). There are now
well-documented prognostic factors that can predict for
poorer survival. The role of more intensive chemotherapy
regimens for these patients has been the subject of much
debate and is currently being assessed by an MRC Trial
(Kaye et al., 1989).
The importance of complete surgical excision of residual
masses after chemotherapy is now accepted and surgeons
experienced in this field may be more likely to perform
adequate resections (Ewing et al., 1987; Hendry et al., 1987;
Whillis et al., 1991).
Most clinicians continue to follow up intensively patients
who have been treated for metastatic NSGCT. The rationale
for this is that second-line chemotherapy may be curative if
the disease is caught early at the time of relapse.
Undoubtedly, some patients may be cured by second-line
chemotherapy, but for others salvage therapy should be
viewed as palliative (Whillis et al., 1991) and opinions vary as
to optimal follow-up for these patients.
The aim of this study was to assess variation in investiga-
tions at the time of diagnosis and subsequently in the man-
agement of patients with both early- and late-stage testicular
NSGCr.
Metbods
Details of all testicular NSGCT cases diagnosed between 1
January 1989 and 31 December 1989 were obtained from the
Scottish Cancer Registration Scheme. Completeness ofregist-
ration and validity of diagnosis was checked by cross-
referring to oncology centre records and is reported in the
accompanying paper (Clarke et al., 1995). A casenote review
was performed on all new cancer registrations for testicular
NSGCT during 1989. Information was extracted on referral
dates, speciality of clinicians involved, staging and pretreat-
ment investigations, histology, prognosis (MRC prognostic
group; Mead et al., 1992), treatment and post-treatment
follow-up for a 2 year period, patient compliance and any
relapse details. Information was recorded onto an agreed
proforma and the data anonymised.
Visits and procedures were considered to be part of a
formal surveillance policy once an 'active' decision had been
documented to pursue such a policy. This was also the
definition for post-treatment follow-up, with both being
measured for 2 full calendar years from the date of the
decision.
Results
Study group
Sixty-five new cases of testicular NSGCT were registered in
Scotland in 1989. Nearly three-quarters of these were aged 34
and under, and only one patient (a paediatric patient treated
at a children's hospital who will not be considered further)
was not referred to a specialist oncology centre. Two patients
(aged 23 and 29) were excluded from the casenote review
because of previous primary testicular tumours. Management
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was therefore not representative of newly diagnosed testicular
NSGCT. The numbers of patients registered at each of the
five centres A-E respectively were four, four, six, 19 and 29.
In only 39 of 62 cases (62.9%) was the place of initial
presentation documented in casenotes. The majority (35
cases, 89.7%) presented to their general practitioner, two to
casualty, one to a psychiatric hospital where he had been
treated for depression and one to a general surgeon. Date of
presentation was not reliably documented so the waiting time
for primary referral could not be measured.
Most patients were initially referred to urological (62.9%)
or general surgeons (35.5%). Secondary referrals were
either to medical oncologists (38.7%), radiation oncologists
(48.4%) or urological surgeons (12.9%).
The median wait for a secondary referral was 13 days,
range 1 112 days. In four cases the delay was over 8 weeks
(71 days, 78 days. 108 days, 112 days). The reasons for these
delays were difficult to interpret but in two cases they may
have been related to urological waiting lists and the other
two patients were misdiagnosed at presentation by general
surgeons as having benign disease.
Details of procedures performed at the time of presenta-
tion are documented in Table I. All patients had a his-
tological diagnosis of either NSGCT or mixed NSGCT and
seminoma.
Staging according to the Marsden system (Peckham et al.,
1979) was assigned by the reviewers in all but two cases.
Thirty-five (56.5%) were stage I, 11 (17.7%) stage II, one
(1.6%) stage III and 13 were stage IV (21.0%). The propor-
tion of patients by stage at presentation varies between cen-
tres but this variation is not statistically significant. The
statistical test may be unreliable however due to the small
numbers involved (i2 = 19.63. d.f. = 12, 0.05<P<0.10).
Management ofstage I disease
Of 35 patients with stage I disease six (17.1%) received
chemotherapy. one (2.9%) received radiotherapy and 28
(80.0%) were placed on surveillance. The six cases receiving
chemotherapy were considered to be at high risk of relapse
because of known poor risk histological features. Three of
these were registered on the MRC high risk stage I trial. The
single case that received radiotherapy was initially diagnosed
as a seminoma.
A surveillance policy was pursued in 28 patients. One died
in a road traffic accident dunrng the first year and seven cases
relapsed (25.0%). Seven of the remainder (35.0%) had
defaults documented in their notes. A patient was considered
to have defaulted if he had missed at least one appointment.
Patients on surveillance excluding defaulters were seen
between eight and 15 times (median 12) during the first year
and three and seven times (median six) during the second
year. At each visit tumour markers alphafetoprotein (AFP)
and human chorionic gonadotrophin (HCG) were performed.
plus a chest radiograph if a computerised tomography (CT)
scan had not been booked around the time of the visit. CT
scans of the thorax and abdomen were performed on zero to
six occasions (median four) in the first year. and zero to three
times (median two) in the second year (Table II). Ultrasound
was not a procedure recorded but some reviewers noted it
had been included in the surveillance programme in a small
number of cases.
Seven (25%) stage I cases relapsed on surveillance, all
within 6 months of diagnosis (median 17 weeks, range 7-22
weeks).
Treatment ofpatients with metastatic disease
Thirty-four patients were treated for metastatic disease. of
which seven were relapsed stage I cases. All cases received
chemotherapy. Four chemotherapy regimens were used for
patients with good prognosis disease, with 10 of 20 such
patients treated within a clinical trial setting. Six regimens
were used for patients with poor prognostic disease with
seven of the 12 treated within a trial setting. A single regimen
was used for the two patients with an unknown prognosis.
During primary therapy only one patient received radio-
therapy. This patient received ten courses of combination
chemotherapy followed by whole brain radiotherapy (4048
cGy in 22 daily fractions over 33 days).
At the end of primary therapy 18 cases (52.9%) had a
complete regression (CR). eleven (32.4%) had partial regres-
sion (PR), one had progressive disease. in three cases the
status was inevaluable (markers normal, no or equivocal CT
scans) and in a further case there was no information.
Sixteen patients did not achieve complete remission at the
end of therapy. Three patients had no further treatment, the
rest having residual masses excised with or without further
chemotherapy. Eleven of the 12 patients who had surgery
achieved a CR.
Defaults from follow-up were recorded in 35% of patients
on active surveillance and 21% of patients with post-
treatment follow-up (27% for all clinic attendances). The
commonest reasons recorded for defaulting were anxiety,
transport difficulties and lack of finance.
There was a marked difference in the number of patients
being treated in a trial setting at a time when almost all
patients would have been eligible for inclusion within MRC
studies. Only two of the five centres entered patients with
69% and 53% of all patients being entered by centres E and
D respectively.
Table I Procedures performed at staging and pretreatment
Performed (as documented in notes) Percentage
Procedure Yes No Not known performed
Pre-operative AFP 51 6 5 82
Pre-operative HCG 51 6 5 82
Pre-operative LDH 10 21 31 16
Post-operative AFP 60 0 2 97
Post-operative HCG 60 0 2 97
Post-operative LDH 18 14 30 29
Ultrasound testis 25 29 8 40
Ultrasound abdomen 14 35 13 23
CT thorax 58 1 3 94
CT abdomen 61 0 1 98
c( brain 1 56 5 2
Chest radiograph 52 4 6 84
MRI 3 56 3 5
Bipedal lymphography 6 52 4 10
CSF markers 0 57 5 0
Biopsy contralateral testis 2 58 2 3
Pathology review 30 27 5 48
Sperm count and or storage 14 36 12 23
Other 6 54 2 10Cuwre manaemet of bstic NSGCT in Scand
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Tae II Frequency of attendance and procedures performed on stage I NSGCT patients on
surveillance (excluding defaulters)
Number ofattendances or procedures
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 NK Total
Year I
Visits 0 0 0 0 0 0 0 0 1 0 3 0 5 1 2 1 0 13
AFP 0 0 0 0 0 0 0 0 1 1 1 1 5 1 3 0 0 13
HCG 0 0 0 0 0 0 0 0 1 11 5 1 3 0 0 13
LDH 5 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 5 13
Chest radiograph 0 0 0 0 1 0 2 3 1 ' 3 0 1 0 0 0 0 13
CT thorax 3 0 0 2 3 2 3 0 0 0 0 0 0 0 0 0 0 13
CT abdomen 1 0 2 2 4 0 0 0 0 0 0 0 O 0 0 13
Year 2
Visits 0 0 0 1 2 3 6 1 0 0 0 00 0 0 0 0 13
AFP 0 0 0 1 2 3 6 1 0 0 0 0 0 0 0 0 0 13
HCG 0 0 0 1 2 3 6 1 0 0 0 00000 0 13
LDH 5 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 5 13
Chest radiograph 0 1 0 2 6 22 00 0 0 0 0 0 0 0 0 13
CT thorax 3 2 7 1 0 0 0 0 0 0 0 0 0 0 0 0 0 13
CT abdomen 3 2 7 1 0 0 0 0 0 0 0 0 0 0 0 0 0 13
NK. not known.
Documentation regarding the patient's first presentation was
poor (only recorded for 63% of cases), but most presented to
their general practitioner and were referred to either a
general or urological surgeon. Secondary referral to onc-
ologists or urological surgeons involved a median wait of 13
days (range 1-112 days) with four cases having delays of
over 8 weeks. Although the reasons for such delays are not
easy to interpret it would appear that in two cases this was
related to urology waiting times. In the other two cases this
was related to an initial diagnosis of benign disease.
The documentation of staging and pretreatment investiga-
tions varied considerably between cases with the frequency of
procedures probably being underrecorded.
Although many clinicians advocate biopsy of the contra-
lateral testis in all patients to exclude carcinoma in situ
(Hargreaves. 1986). this was only performed in 3% of cases.
This highlights the reluctance of surgeons to inflict another
invasive procedure on their patients and the controversy
surrounding the necessity for biopsy. Investigations per-
formed at presentation for diagnosis and staging are predic-
table. Lactate dehydrogenase is rarely measured, which
illustrates the controversy as to how valuable this is.
Although a non-specific marker, high levels are indicative of
a poor prognosis and it may be the only marker in
seminoma. As a general rule there is no role for abdominal
ultrasound now that CT scanning is widely available. MRI
has only recently been introduced and it is not clear as to
whether it has any advantage over CT in the management of
the disease.
Facilities for sperm storage are available in four of the five
centres. Centre A is the exceptions sending sample, to centre
B for storage. This was not performed in all patients receiv-
ing chemotherapy. There may be good but undocumented
reasons for this (e.g. previous vasectomy or clinical urgency
to commence treatment). Although the majonrty of patients
with normal sperm counts before therapy will regain fertility
after chemotherapy, facilities for storage of sperm should be
readily accessible for all patients.
There is considerable variation in the frequency of follow-
up and investigations performed when patients are managed
on an active surveillance policy. Although there will be many
reasons for increasing the frequency of investigations in
specific patients there should be a minimum number of atten-
dances and investigations which is considered to be good
practice. The variation in CT scanning of the abdomen
between zero and six times and zero and three times in the
first and second year respectively is of concern.
The incidence for defaulting from surveillance and post-
treatment follow-up is worryingly high with 35.0% and
21.40o of cases defaulting respectively. Patients on surveil-
lance in another study have been found to be less compliant
compared with those having received chemotherapy as they
underestimated the need for follow-up (Young et al.. 1991).
It is therefore important that only those who are reliable are
selected for active surveillance. Some assistance in the form
of transport or counselling regarding the importance of
follow-up may be necessary.
Chemotherapy regimens for both poor and good risk
patients with metastatic disease were largely predictable.
Four different regimens for good prognosis disease were
used. all are well recognised but vary considerably in their
toxicity. Such variation should not exist outside clinical trials
and it is noteworthy that only 10 of 20 patients were treated
in a trial setting. There should be a consensus as to the most
appropriate first-line therapy unless patients are entered into
a trial. Six regimens were used for patients with poor prog-
nostic disease with seven out of 12 in trials. Only two of the
five centres put patients into clinical trials. The three centres
which did not participate stated that this was due to lack of
clerical support in 1989. but with the recent introduction of
the Scottish Cancer Therapy Network (SCTN) this issue has
already been addressed.
The importance of complete resection of residual masses
after chemotherapy is well documented. In this study a total
of 12 operations were undertaken in a single year by three
urological surgeons. one cardiothoracic and two general
surgeons in three centres. It may be that with this level of
workload such surgery should be performed by fewer
surgeons.
Referral patterns in general were predictable but unaccep-
table delays occurred in a small number of cases awaiting
surgery. In at least two cases this was due to the patients
being diagnosed as having benign disease and to avoid such
delays there should be a high index of suspicion that patients
with testicular symptoms might have cancer and are treated
urgently.
This study has highlighted considerable variation in several
different aspects of the management of NSGCT in Scotland.
Follow-up policies for patients on surveillance as well as
those after chemotherapy varied considerably and guidelines
should be laid down as to what is the minimum advisable
with regard to clinic appointments and investigations.
Defaults from surveillance and follow-up occurred too often
and arrangements for transport or other financial support
and psychological support should be made available.
Multiple chemotherapy regimens were used for patients
with both good and poor prognostic disease. Although there
will always be reasons for tailoring chemotherapy to individ-
ual patients national guidelines for first- and second-line
chemotherapy for patients not entered into a trial protocolConeuid N-agsmnut dUskdw NT i Scdu,d
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might result in a more consistent approach to the manage-
ment of this disease.
The trial entry is poor for a rare tumour at a time when
almost all patients woiuld have been eligible for one trial or
another. There is a particularly noticeable variation in trial
entry between centres. The reasons for this relate to lack of
clerical and other support and this should improve following
the setting up of the Scottish Cancer Therapy Network.
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